The Anti-KIT Antibody, CDX-0159, Reduces Mast Cell Numbers and Circulating Tryptase and Improves Disease Control in Patients with Chronic Inducible Urticaria (Cindu)

Abstract

Mast cells (MCs) are effector cells that mediate chronic urticaria, including CIndU. MC differentiation, proliferation, and survival require activation of KIT receptors by stem cell factor (SCF). CDX-0159 is a humanized monoclonal antibody (mAb) inhibiting SCF-dependent KIT activation. A single 3mg/kg IV dose demonstrated a 95% complete response (negative provocation testing) in CIndU patients and was generally well tolerated as presented previously. Here, we present CDX-0159 effect on urticaria control, pharmacodynamics (PD), and pharmacokinetics (PK).